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ABSTRACT 
Objective: The objective of the present study was to develop and optimize the methods for preparation and characterization of the liposomal 
delivery system of natural heme protein. 
Methods: Cytochrome C containing liposomes (Cyt-LS) were prepared by high-pressure homogenization technique using phosphatidylcholine (PC) 
and dipalmitoyl phosphatidylglycerol (DPPG). Nanoparticles were characterized by using: dynamic light scattering, zeta potential measurements, 
scanning electron microscopy and HPLC. The specific activity was studied in vitro. 
Results: The study of homogenization regimes for obtaining unilamellar Cyt-LS was carried out. The selected temperature regime of 
homogenization was kept within 38–44 °С with optimal homogenization pressure of 800 bar. The obtained Cyt-LS were characterized by the main 
physicochemical parameters showed: Encapsulation efficiency 95.8±2.0%, Zeta potential-57±1.0 mV, pH-6.95±0.05. Phospholipid impurities had 
the following content: lysophosphatidylcholine-0.60±0.05% and free fatty acids-0.4±0.05%. The average particle diameter was 156±2 nm. Also, the 
size of Cyt-LS particles was confirmed by the ability of emulsion subjected to the sterilizing filtration with the preservation of its main 
physicochemical properties. Cyt-LS exhibit specific activity, similar to non-liposomal Cyt-C solution.  
Conclusion: The formulation of the liposomal delivery system of heme protein was successfully prepared using natural components and evaluated 
for different parameters.  
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One of the known natural heme protein involved in the respiratory 
electron transport chain and cell apoptosis is cytochrome C (Cyt-C). 
Cyt-C is also involved in the removal of superoxide (О2-) and 
hydrogen peroxide Н2О2
 
 from mitochondria, acting as an 
antioxidant enzyme. [1-3] (fig. 1)  
 
Fig. 1: Removal of O2-and H2O2
 
 by cytochrome c 
The ability to capture and neutralize reactive oxygen species (ROS) 
defines some properties of Cyt-C as a medical preparation for the 
prevention and treatment of the oxidant-induced injury caused by 
ROS formation under oxidative stress which often accompanies the 
processes of tissue hypoxia. There are the following Cyt-C containing 
drugs on the world pharmaceutical market used for the treatment of 
cardiological and ophthalmologic diseases, e. g. in preparations like 
“Oftan catachrom” (Santen), “Cytochrome C Eye Drops” (Samson-
med), “Cytochrome C for injection” (Pharmstandard biolik) 
“Ractovit” (Ibn Sina),“Vitafol” (Popular Pharmaceuticals). 
However, the water-soluble Cyt C form has a number of significant 
drawbacks: Cyt C insignificantly penetrates cells through biological 
membranes and is rapidly removed from parts of the body damaged 
by hypoxia, which causes its extremely low bioavailability after 
administration. At the same time, under hypoxia, the structural 
damage leads to the simultaneous loss of Cyt-C and phospholipids in 
the mitochondrial respiratory chain [4]. 
Liposomes (LS) are of special importance among modern drug 
delivery systems. Phospholipids derived from natural sources of 
plant or animal origin (e. g. soybeans or chicken eggs) are often used 
as the main component of the liposomal membrane. LS derived from 
phospholipids of natural origin have a number of undoubted 
advantages: they are nonimmunogenic, low-toxic and under certain 
conditions can connect with the phospholipids of cell membranes 
and deliver their contents inside the cells [5, 6].  
LS can act as a delivery system of small molecules [7, 8] as well as 
various macromolecules with a molecular mass of more than 10 kDa 
including various heme proteins (hemoglobin, cytochromes) [9-12]. The 
earlier in vivo studies of Cyt-LS confirm the greater efficacy of using Cyt-
LS in comparison with Cyt-C non-liposomal form after instillation of eye 
and parenteral administration [12-15]. Thus, the feasibility of developing 
a Cyt-C encapsulated in LS (Cyt-LS) dosage form consisting of natural 
phospholipids is obvious. However, the preparation and characterization 
of such liposomal systems as medicines in accordance with modern 
requirements for the pharmaceutical industry [16-19] is quite a 
challenge. High molecular mass, special structure and sensitivity to heat 
of all heme proteins will largely determine the approaches to obtain such 
liposomal systems as medicines. 
The objective of the present study was to develop and optimize the 
methods for the preparation and characterization of the liposomal 
delivery system of natural heme protein. 
MATERIALS AND METHODS 
Materials 
Cytochrome C (Farmasino pharmaceuticals Co., ltd, China), Egg 
Phosphatidylcholine, Lipoid E 100 (Lipoid GmbH, Germany), 
dipalmitoyl phosphatidylglycerol (DPPG-Na) (Lipoid GmbH, 
Germany), phosphatidylcholine standard Lipoid E PC RS (Lipoid 
GmbH, Germany), dipalmitoyl phosphatidylcholine standard DPPG-
Na RS (Lipoid GmbH, Germany), lysophosphatidylcholine (Lipoid 
GmbH, Germany), chloroform (Sigma Aldrich), methanol (Sigma 
Aldrich), potassium dihydrogen phosphate (Fluka), sodium 
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dihydrogen phosphate (Sigma Aldrich), disodium hydrogen 
phosphate (Sigma Aldrich). 
Preparation of cytochrome C containing liposomes 
DPPG-Na and ЕРС were dissolved in chloroform: ethanol mixture 
(4:1). The mixture was evaporated on a BUCHI Rotavapor R215 
rotary evaporator (Switzerland) until a lipid film was formed. The 
lipid film was hydrated with a Cyt C solution, on an IKA werke 
orbital shaker (Germany) until a homogeneous emulsion of 
multilamellar liposomes was formed. The resulting emulsion of 
multilamellar drugs was homogenized on a high-pressure 
homogenizer-microfluidizer M110P (USA) [20, 21]. 
Then the obtained LS-Cyt were subjected to sterilizing filtration in a 
clean room. Filtration possibility was evaluated on PALL (USA) 
polyethersulfone filters with 0.22 μm pore size. 
Physicochemical characterization of liposomes 
Particle size (DLS) and zeta potential were determined on a Malvern 
zetasizer nano ZS (UK). The pH of the liposomal emulsion with Cyt C was 
measured on a Schott instruments Lab860 pH meter (Germany) [22]. 
Scanning electron microscopy  
LS-Cyt imaging was performed by scanning electron microscopy 
[23]. A sample of Cyt-LS was applied to a copper mesh covered with 
a thin carbon layer. The sample was contrasted with 2% uranyl 
acetate solution. Next, the sample was tested on a Tescan Mira 3 
LMU (Czech Rep.) using a STEM detector which allows conducting 
studies in scan mode with detection of the signal that passed 
through the sample. 
Phospholipids and their impurities assay 
(lysophosphatidylcholine, free fatty acids) 
The content of phospholipids in liposomes was determined by HPLC 
[24] on a Shimadzu chromatograph (Japan), under the following 
conditions: PerfectChrom 100 Diol column of 0.125x4 mm, 5 µm, 
with column temperature of 55 °C, ELSD Sedere SEDEX 85 detector 
(France), sample volume of 20 µl, Mobile phase A: 1341.6 g of n-
hexane, 334.1 g of 2-propanol, 39.4 g of acetic acid, and 1.45 g of 
triethylamine. Mobile phase B: 663.5 g of 2-propanol, 140.0 g of 
water, 15.8 g of acetic acid, and 0.58 g of triethylamine. The gradient 
elution program is shown in table 1. 
 
Table 1: The gradient elution program 
Time (min) Flow rate (ml/min) Mobile phase A:  (% vol) Mobile phase B (% vol) 
0 1.0 95 5 
5.0 1.0 80 20 
8.5 1.0 60 40 
15.0 1.0 0 100 
17.5 1.0 0 100 
17.6 1.0 95 5 
21.0 1.0 95 5 
22.0 2.0 95 5 
27.0 2.0 95 5 
29.0 1.0 95 5 
Phospholipids included in liposomes and phospholipid standards were dissolved in chloroform: methanol: water (74:23:3), The content of 
phospholipids was calculated by PC, DPPG-Na, lysophosphatidylcholine (LPC) and Free fatty acids calibration graphs.  
 
Encapsulation efficiency studies 
The total amount of Cyt C (Cyt C total) was quantified with a 
spectrophotometric method on a Shimadzu UV1800 
spectrophotometer (Japan) using the UV absorption spectrum of 
diluted Cyt-LS in the range of 400-560 nm. The determination of 
non-liposomal Cyt C (Cyt C free) was evaluated by gel 
chromatography method. Shimadzu "Nexera" chromatograph was 
used, a Tricorn chromatographic column of 5/200 size (Ge 
Healthcare) filled with a "superose 12" sorbent. Mobile phase: 4.515 
g/l KH2PO4
The percentage of encapsulation efficiency was determined by using the 
ratio amount of entrapped Cyt C “Cyt C total–Cyt C free” to the amount of 
total Cyt C, which may be expressed by the following formula:  
 pH up to 6.0 2M NaOH; flow rate 0.5 ml/min; detection 
409 nm; column temperature of 25 °C. Solutions of Cyt-C substance 
and Cyt-LS were chromatographed separately  
 
Sterility evaluation 
Sterility evaluation was performed by the method of membrane 
filtration [25]. LS-Cyt was filtered through two pre-moistened 
membrane filters. After the filtration was finished, the filters were 
washed with sterile water. Then one tank of the sterilization system 
was filled with thioglycolic, and the second with soy-casein nutrient 
media. Next, inoculations in the thioglycolic medium were incubated at 
a temperature of 30-35 °C, and in the soy-casein medium, at a 
temperature of 20-25 ° C., all the inoculations were incubated for 14 d. 
In vitro activity study 
UV absorption spectra of the reduced and oxidized forms of the LS-
Cyt solution were compared with the solution of cytochrome C 
substance in the range of 190-600 nm on Shimadzu UV1800 
spectrophotometer (Japan). 
The reduced form of cytochrome C was obtained by adding sodium 
dithionite to the aqueous solutions of LS-Cyt and Cyt substance. 
After that, cytochrome C was oxidized by adding potassium 
ferricyanide to the same solutions [26] 
RESULTS AND DISCUSSION 
Preparation of cytochrome C containing liposomes 
It is well known that Cyt-C can form complexes with anionic 
phospholipids in biological membranes [27-29], which is 
determinant in Cyt-C protein-lipid interaction. Based on these data, 
anionic phospholipid-dipalmitoyl phosphatidylglycerol (DPPG) was 
used in the composition of nanoparticles. Phosphatidylcholine (PC), 
the main component of eukaryotic membranes, was used as a 
membrane-forming lipid. The technological scheme of LS-Cyt 
production comes down to the preparation of a lipid film and its 
emulsification in Cyt-C solution to obtain an emulsion of 
multilamellar vesicles, followed by high-pressure homogenization 
until unilamellar vesicles were obtained.  
Critical quality attributes (CQAs) of the liposomal product are: 
encapsulation efficiency of the active substance, particle size, and 
liposomal nanoparticles morphology. One of the key factors of the 
technology influencing these indicators is the choice of the method 
of unilamellar vesicles production. Today, one of the main industrial 
methods for obtaining small unilamellar liposome vesicles with 
active pharmaceutical ingredients included is high-pressure 
homogenization. The advantage of this method, in comparison with 
the methods of ultrasound, freeze-thaw, injection, etc., is the 
standard approaches and potential scaling ability to large-scale 
production, high yield, minimal oxidation and hydrolysis of 
phospholipids, integrity of the drug, stability of the resulting 
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liposomes and control over key parameters in the technology 
process [30-32]. The selected homogenization mode may allow 
obtaining liposomes of standard composition, the bulk of which is 
represented by particles no larger than 200 nm. In addition to 
pharmacological properties, such liposome size will also determine 
the possibility of carrying out a sterilizing filtration process.  
The optimal temperature regime of homogenization was kept within 
38–44 °С. Firstly, such a temperature range is above the transition 
phase temperature of the phospholipids used, secondly, it is 
maximum close to temperature values at which Cyt-LS is in 
biological systems. In addition, natural phospholipids which are the 
main component of LS are also quite sensitive to the temperature 
increase at which the increase in degradation products (LPC and free 
fatty acids) can be observed. [33, 34] 
The choice of optimal pressure, on one hand, was aimed to obtain the 
minimum number of homogenization cycles required to have the main 
LS mass up to 200 nm-which allows sterilizing filtration. On the other 
hand, the choice of the optimal pressure level was supposed to prevent 
the selected temperature regime from exceeding. Thus, 
experimentally, the pressure level was selected within 800 bar.  
Physicochemical characterization of liposomes 
Particle size control during homogenization was performed using 
the DLS method (fig. 2) 
 
 
а. Two homogenization cycles     b. Three homogenization cycles 
 
c. The final homogenization cycle 
Fig. 2: Particle size control during homogenization a-Cyt-LS after two homogenization cycles, b-Cyt-LS after three homogenization cycles, 
c-Cyt-LS after the final homogenization cycle 
 
Dynamic light scattering (DLS), is broadly used in liposome size 
distribution analysis. The strengths of the technique include the 
ability to make measurements in the original state of liposomes; its 
sensitivity; ease of commercially available operating instrument; 
minimal sample volume, concentration and preparation 
requirements; large size range of species spanning up 1 nm to 
several μm. However, the technique does not yield particle shape 
information; it can yield a bias towards reporting larger diameters 
when small quantities of high molecular weight or aggregates or 
impurities are present in the sample [35, 36]. 
After homogenization, Cyt-LS were characterized to confirm 
homogeneity by a number of parameters including encapsulation 
efficiency, lipid composition content, surface charge, and particle 
size assessment.  
As a result, the mean particle of Cyt-LS were observed to be 
156.6±0.02 (mean±SD, n = 3). Lysophosphatidylcholine content 
(from the amount of lipids): (LPC) of 0.60±0.05% (mean±SD, n = 3), 
free fatty acids — 0.40±0.05% (mean±SD, n = 3).  
Encapsulation efficiency studies 
The liposome preparations are a mix of encapsulated and non-
encapsulated drug fractions. The first step for the determination of the 
encapsulation efficiency is the separation between the encapsulated 
drug (within the carrier) and the non-encapsulated. Gel 
chromatography methods can be applied for the determination of the 
encapsulation efficiency [37, 38]. In this case, the encapsulation 
percent can be expressed as the ratio of the un-encapsulated peak area 
to that of a reference standard at the same initial concentration. 
To determine the encapsulation efficiency, methods for determining 
the total Cyt-C concentration and the concentration of non-
encapsulated Cyt-C were proposed. 
The total concentration of Cyt-C in Cyt-LS (Сyt total) was determined 
spectrophotometrically using the UV absorption spectrum of a 
diluted Cyt-LS emulsion in the range of 400–560 nm (fig. 3). 
The determination of "non-encapsulated" Cyt-C (Cyt free) was 
performed by gel chromatography method. 
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Fig. 3: UV-spectrum of Cyt-LS 
 
 
a. Cyt-C (Non-liposomal) 
 
b. Cyt-LS 
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c. Placebo Cyt-LC (Without Cyt-C) 
Fig. 4: 3D Chromatograms of Cyt-C standard, Cyt-LS and Cyt-LS placebo solutions: a-3D chromatogram of a Cyt-C standard solution (non-
liposomal); b-3D Cyt-LS chromatogram; c-3D placebo Cyt-LS chromatogram (without Cyt-C) 
 
As can be seen from Fig. 4 the main peaks in Cyt-LS and non-
liposomal Cyt-C chromatograms have different retention times. 
The characteristic maximum of the UV spectrum in the 400–410 
nm ranges is observed in the standard Cyt-C solution peaks 
spectra of (200–800 nm) and Cyt-LS (200–800 nm), which 
confirms the encapsulation of Cyt-C in liposomes. As a result, Cyt-
LS were obtained with encapsulation efficiency 95.8±0.02% 
(mean±SD, n = 3) 
  
  
Fig. 5: SEM images of Cyt-LS 
 
Scanning electron microscopy  
Controlling and confirming the nanoparticles morphology is also key 
to the effective clinical use of LS drugs. Currently, there are a lot of 
visualization methods for evaluating LS and other nanoparticle 
morphology, each of which has its advantages and disadvantages 
that should be considered when interpreting the data. One of such 
visualization method is Scanning Electron Microscopy, SEM. We use 
SEM with a STEM detector, which allows conducting research in a 
scanning mode with the detection of a signal that passed through a 
sample. The results of the study are presented in fig. 5. On the 
obtained images LS have an average size of about 200 nm. 
Sterility evaluation 
The potential use of Cyt-LS in clinical practice as a medical substance 
and its long-term storage will be connected with obtaining sterile LS. 
To ensure the production of sterile LS there is the possibility to 
obtain LS under aseptic conditions, carrying out thermal sterilization 
or sterilizing filtration [39]. In the first case, it will be necessary to 
ensure that all technological operations are performed in order to 
obtain LS under sterile conditions starting from the stage of 
obtaining a lipid film and its rehydration with sterile Cyt-C buffer 
solution, which in turn will entail quite considerable costs on 
implementation of this scheme for obtaining LS [40]. 
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Thermal sterilization will involve LS sterilization at 121 °C for 10–30 
min. At the same time, the use of thermal sterilization will be 
determined by a number of factors: the lipid LS composition and 
their oxidative stability; the heat resistance of substances included 
in LS. An additional problem unique to liposomes is the resultant 
leakage of encapsulated contents [41, 42]. Therefore it will obviously 
have a negative impact on the use of natural phospholipids and 
biologically active proteins, which are quite sensitive to heating at 
high temperatures. 
The method of sterilizing filtration involves the filtering of liposome 
preparations through sterile filtration units (0.22 μm) under 
pressure, allowing liposomes smaller than 200 nm to pass through. 
This sterilization technique is suitable for thermolabile API (for 
example hemeproteins) since it does not involve any form of heating 
nor conditions that can result in the formation of degradation 
products or leakage of liposomal contents associated with the other 
terminal sterilization techniques. One drawback of this technique is 
size restriction limits of LS which are suitable for filtering. However, 
this limitation is insignificant in manufacturing liposomes for 
parenteral usage since a small vesicle size (of<500 nm) [43] is 
recommended to minimize complications such as retention and 
trapping of the vesicles in the narrower capillaries. Unfortunately, all 
the other conventional techniques result in the formation of 
degradation products via the aforementioned degradation pathways. 
The physical and chemical complexity of LS drugs creates unique 
challenges for the sterilization filtration process [44, 45]. The LS 
components can, for example, interact with the filter matrix or, 
having an average particle size exceeding 0.22 μm, can block it up. At 
the same time, conducting sterilizing filtration allows 
standardization of LS preparations. 
We have evaluated the sterilization filtration. Cyt-LS in the amount 
of 1 liter was subjected to sterilizing filtration through Pall (USA) 
0.22 μm membrane filters. After sterilizing filtration, the main 
indicators of LS product quality were monitored. The comparison is 
shown in table 2. The sterility of the obtained product was also 
assessed by membrane filter assay. Thus, the obtained LS-Cyt can be 
subjected to sterilizing filtration with the preservation of the main 
physicochemical properties. 
 
Table 2: Study of sterilizing filtration of Cyt-LS before and after sterilizing filtration 
Test Cyt-LS before sterilizing filtration 
(mean±SD, n = 3) 
Cyt-LS after sterilizing filtration 
(mean±SD, n = 3) 
Encapsulation efficiency,% 95.8±0.02 95,8±0.02 
Mean particle size, nm 156.6±0.02 157.3±0.02 
Zeta potential, mV -57±0.10 -57±0.10  
рН 6,95±0.05 6,91±0.05 
LPC, % 0,60±0.05 0,59±0.05 
Free fatty acids,% 0,4±0.05  0,39±0.05 
Cyt C, % 100,1±0.05 100,3±0.05 
PC, % 99,8±0.05 99,6±0.05 
DPPG-Na, % 100,2±0.05 100,0±0.05 
Sterility  - Pass 
 
 
Fig. 6: UV-spectrum of LS-Cyt 
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Fig. 7: UV-spectrum of Cyt solution 
 
In vitro activity study 
We also evaluated the reactivity of Cyt-C which is primarily regarded 
as its activity in providing electron transport function in 
mitochondria respiratory chain. The specific activity study was 
performed in vitro. The reaction with sodium dithionite (Na2S2O4
After adding sodium dithionite the absorption maxima at 520 and 
550 nm identically appear in the UV spectra of LS-Cyt and Cyt 
solutions. That corresponds to the characteristic UV spectrum for all 
types of Cyt in a reduced state [48]. 
) is 
used to determine Cyt-C activity in Cyt-C solutions for injection [46]. 
The ability of Cyt to transfer from the reduced to oxidized form was 
evaluated by adding potassium ferrocyanide to the solution of Cyt-C 
in the reduced form [47]. To compare the specific activity of Cyt-LS, 
the spectra of the LS-Cyt solution that were reduced with sodium 
dithionite and oxidized ferrocyanide were compared with the 
spectra of a non-liposomal Cyt-C solution in reduced and oxidized 
forms respectively fig. 6, 7. 
Thus, the obtained UV spectra demonstrate that Cyt-LS retains the 
ability to receive and release electrons, similarly to a non-liposomal 
Cyt solution. 
CONCLUSION 
Applications of heme proteins in medicine can be improved through 
liposomal delivery systems. However, the preparation and 
characterization of such systems as medicines in accordance with 
modern requirements for the pharmaceutical industry is quite a 
challenge. This project was conducted to study the methods for the 
preparation and characterization of heme protein containing a 
liposomal delivery system consisting of natural components, for its 
potential use in the prevention and treatment of oxidant-induced 
injuries. Thus, preclinical and a clinical trial is required for the future 
development of this formulation.  
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